Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Plasma Cell Myeloma Recurrent”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT03711864
What this trial is testing

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Who this might be right for
Multiple Myeloma
Peking Union Medical College Hospital 15
Very early researchLooking for participantsNCT07519187
What this trial is testing

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Who this might be right for
Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command 20
Large-scale testing (Phase 3)Looking for participantsNCT07623798
What this trial is testing

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd. 255
Testing effectiveness (Phase 2)Study completedNCT00109993
What this trial is testing

Campath-1H + FK506 and Methylprednisolone for GVHD

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Case Comprehensive Cancer Center 34
Early research (Phase 1)Ended earlyNCT02223598
What this trial is testing

Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

Who this might be right for
Lymphoid Hematological MalignanciesRelapsed and Refractory Multiple Myeloma
Cleave Biosciences, Inc. 120
Early research (Phase 1)Study completedNCT01497093
What this trial is testing

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 34
Early research (Phase 1)Study completedNCT03829020
What this trial is testing

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 9
Testing effectiveness (Phase 2)Looking for participantsNCT06832865
What this trial is testing

ELISA in Relapsed/Refractory MM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02348528
What this trial is testing

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Who this might be right for
Multiple Myeloma
Celgene 65
Early research (Phase 1)Study completedNCT00118170
What this trial is testing

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt Lymphoma+42 more
National Cancer Institute (NCI) 150
Testing effectiveness (Phase 2)Looking for participantsNCT07657312
What this trial is testing

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Who this might be right for
Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma
Naresh Bumma 35
Testing effectiveness (Phase 2)Study completedNCT02633059
What this trial is testing

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Loss of Chromosome 17pRecurrent Plasma Cell Myeloma
Mayo Clinic 33
Testing effectiveness (Phase 2)Looking for participantsNCT07681596
What this trial is testing

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AstraZeneca 101
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Not applicableStudy completedNCT05217082
What this trial is testing

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 35
Testing effectiveness (Phase 2)Ended earlyNCT02075021
What this trial is testing

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
NYU Langone Health 3
Testing effectiveness (Phase 2)Study completedNCT03361748
What this trial is testing

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 149
Very early researchNot Yet RecruitingNCT07234721
What this trial is testing

SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 9
Testing effectiveness (Phase 2)Study completedNCT02086552
What this trial is testing

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 28
Next Page